Miles Clements, a partner at VC firm Accel, said there are two reasons Claude's latest improvements don't hurt Cursor.
TIX100 is a specific, orally available TXNIP inhibitor originally developed for its beta-cell protective effects in diabetes. It has received FDA Investigational New Drug approval in diabetes and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results